High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 684-689

  Chihara, Dai ^a   Izutsu, Koji ^b   Kondo, Eisei ^c   Sakai, Rika ^d   Mizuta, Shuichi ^e   Yokoyama, Kenji ^f   Kaneko, Hiroto ^g   Kato, Koji ^h   Hasegawa, Yuichi ⁱ   Chou, Takaaki ^j   Sugahara, Hiroyuki ^k   Henzan, Hideho ^l   Sakamaki, Hisashi ^m   Suzuki, Ritsuro ⁿ   Suzumiya, Junji ^o  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^j NIIGATA CANCER CENTER HOSPITAL   (Japan)

^k SUMITOMO HOSPITAL   (Japan)

^l HAMANOMACHI HOSPITAL   (Japan)

^m TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁿ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o SHIMANE UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Autologous stem cell transplantation; Diffuse large Bcell lymphoma; Elderly patients; Relapse refractory

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; RANIMUSTINE; NITROSOUREA DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA; RELAPSED DIFFUSE LARGE B CELL LYMPHOMA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; NITROSOUREA COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84897960368     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.01.025     Document Type: Article

References (27)

1. Swerdlow S., Campo E., Harris N., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer (IARC), Lyon, France.
2. Aoki R., Karube K., Sugita Y., et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int 2008, 58:174-182.
3. A predictive model for aggressive non-Hodgkin's lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993, 329:987-994.
4. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
5. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002, 346:235-242.
6. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. JClin Oncol 2005, 23:5027-5033.
7. Vose J.M., Zhang M.J., Rowlings P.A., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. JClin Oncol 2001, 19:406-413.
8. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995, 333:1540-1545.
9. Mounier N., Canals C., Gisselbrecht C., et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012, 18:788-793.
10. Wildes T.M., Augustin K.M., Sempek D., et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:840-846.
11. Jantunen E., Canals C., Rambaldi A., et al. Autologous stem cell transplantation in elderly patients (> or=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood andMarrow Transplantation registry. Haematologica 2008, 93:1837-1842.
12. Atsuta Y., Suzuki R., Yoshimi A., et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007, 86:269-274.
13. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JClin Oncol 1999, 17:1244.
14. Imai Y., Chou T., Tobinai K., et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant 2005, 35:479-487.
15. Yamamoto K., Taji H., Kagami Y., et al. LEED therapy followed by auto PBSCT for aggressive and relapsed malignant lymphoma. Rinsho Ketueki 2006, 9:1022.
16. Fine J.P. Regression modeling of competing crude failure probabilities. Biostatistics (Oxford, England) 2001, 2:85-97.
17. Kaplan E.L., Meire P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
18. Zhang M.J. Cox proportional hazards regression models for survival data in cancer research. Cancer Treat Res 2002, 113:59-70.
19. Friedberg J.W. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011:498-505.
20. Jantunen E., Itala M., Juvonen E., et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006, 37:367-372.
21. Gopal A.K., Gooley T.A., Golden J.B., et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001, 27:593-599.
22. Artz A.S., Pollyea D.A., Kocherginsky M., et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12:954-964.
23. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
24. Tucci A., Ferrari S., Bottelli C., et al. Acomprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009, 115:4547-4553.
25. Fenske T.S., Hari P.N., Carreras J., et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009, 15:1455-1464.
26. Martin A., Conde E., Arnan M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
27. Armitage J.O., Carbone P.P., Connors J.M., et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. JClin Oncol 2003, 21:897-906.